Xi Cheng

700 total citations
18 papers, 531 citations indexed

About

Xi Cheng is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xi Cheng has authored 18 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 11 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Xi Cheng's work include RNA modifications and cancer (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer-related molecular mechanisms research (4 papers). Xi Cheng is often cited by papers focused on RNA modifications and cancer (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer-related molecular mechanisms research (4 papers). Xi Cheng collaborates with scholars based in China, United States and Japan. Xi Cheng's co-authors include Ziliang Wang, Yufei Yang, Zihao Qi, Haoran Li, Huizhen Sun, Xinjing Wang, Fei Liu, Lihua Chen, Gong Yang and Husheng Wang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Oncogene.

In The Last Decade

Xi Cheng

18 papers receiving 528 citations

Peers

Xi Cheng

ONCOL

IMMUN

Núria Eritja Spain

Baoen Shan China

Tingting Chen China

Stella Logotheti Germany

Guosong Jiang China

Juanni Li China

Yung-Chieh Chang Taiwan

Stephanie Cabarcas‐Petroski United States

James Huber United States

Marco Pieraccioli Italy

Núria Eritja Spain

Xi Cheng

449 ×1.3

202 ×0.9

191 ×1.3

ONCOL

94 ×1.4

IMMUN

95 ×1.6

Citations per year, relative to Xi Cheng Xi Cheng (= 1×) peers Núria Eritja

Countries citing papers authored by Xi Cheng

Since Specialization

Citations

This map shows the geographic impact of Xi Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xi Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xi Cheng more than expected).

Fields of papers citing papers by Xi Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xi Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xi Cheng. The network helps show where Xi Cheng may publish in the future.

Co-authorship network of co-authors of Xi Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Xi Cheng. A scholar is included among the top collaborators of Xi Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xi Cheng. Xi Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wei, Haiyan, Wenjuan Dai, Wenjuan Yu, et al.. (2025). DM005: An anti-EGFR/c-MET bispecific antibody-drug conjugate for advanced solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 2 indexed citations

Yang, Yufei, Lingfang Xia, Yong Wu, et al.. (2021). Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Communications. 41(6). 511–527. 42 indexed citations

Li, Haoran, Zihao Qi, Yongdong Niu, et al.. (2021). FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer. Oncogene. 40(40). 5938–5949. 40 indexed citations

Li, Xiaoduan, Yi Zhang, Xinjing Wang, et al.. (2021). Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2. Cell Biology and Toxicology. 38(6). 1027–1045. 21 indexed citations

Sun, Huizhen, Husheng Wang, Xue Wang, et al.. (2020). Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics. 10(15). 6928–6945. 101 indexed citations

Li, Haoran, Hong Dai, Tingyan Shi, et al.. (2020). Functional genetic variants of CTNNBIP1 predict platinum treatment response of Chinese epithelial ovarian cancer patients. Journal of Cancer. 11(23). 6850–6860. 7 indexed citations

Chen, Lihua, Xi Cheng, Wenzhi Tu, et al.. (2019). Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cellular Oncology. 42(5). 679–690. 41 indexed citations

Li, Haoran, Yuan Xu, Mengyun Wang, et al.. (2019). Functional genetic variants of RUVBL1 predict overall survival of Chinese patients with epithelial ovarian cancer. Carcinogenesis. 40(10). 1209–1219. 7 indexed citations

Yang, Yufei, Yue Cao, Lihua Chen, et al.. (2018). Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells. Cancer Medicine. 7(9). 4610–4618. 68 indexed citations

10.

Xu, Yuan, Lei Cheng, Hong Dai, et al.. (2018). Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer. Journal of Cellular and Molecular Medicine. 22(10). 4975–4984. 9 indexed citations

11.

Li, Haoran, Shuang Hu, Yangyang Pang, et al.. (2018). Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin β2/FAK signaling pathway in ovarian cancer.. PubMed. 8(7). 1288–1296. 23 indexed citations

12.

Li, Haoran, Mengjiao Li, Yangyang Pang, et al.. (2017). Fructose-1,6-bisphosphatase-1 decrease may promote carcinogenesis and chemoresistance in cervical cancer. Molecular Medicine Reports. 16(6). 8563–8571. 10 indexed citations

13.

Shi, Tingyan, Pan Wang, Caixia Xie, et al.. (2017). BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Association of ethnic-specific mutations in BRCA1 with an increased risk of ovarian cancer.. Journal of Clinical Oncology. 35(15_suppl). 1583–1583. 2 indexed citations

14.

Shi, Tingyan, Jing He, Zhi Ming Shao, et al.. (2015). CASP7 variants modify susceptibility to cervical cancer in Chinesewomen. Scientific Reports. 5(1). 9225–9225. 13 indexed citations

15.

Zhang, Wen, Fei Liu, Dawei Li, et al.. (2015). RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis. Oncotarget. 7(5). 5800–5814. 38 indexed citations

16.

Shi, Tingyan, Li Yang, Gong Yang, et al.. (2013). DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. Medical Oncology. 30(2). 500–500. 16 indexed citations

17.

Shi, Tingyan, Gong Yang, Ji Qian, et al.. (2012). RAD52 Variants Predict Platinum Resistance and Prognosis of Cervical Cancer. PLoS ONE. 7(11). e50461–e50461. 25 indexed citations

18.

Yang, Gong, Xue Xiao, Daniel Rosen, et al.. (2011). The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer. Clinical Cancer Research. 17(8). 2181–2194. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact